DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV Infection Genotype 1)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir, dasabuvir
Drug: sofosbuvir (SOF)
Drug: ribavirin (RBV)

First Posted Date: 2015-03-26

Last Posted Date: 2016-12-12

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02399345

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML)
Multiple Myeloma
Non-Hodgkins Lymphoma
Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Small Cell Lung Cancer
Breast Cancer

Interventions: Drug: ABBV-075
Drug: Venetoclax

First Posted Date: 2015-03-18

Last Posted Date: 2019-11-29

Lead Sponsor: AbbVie

Target Recruit Count: 128

Registration Number: NCT02391480

Locations: 🇺🇸
City of Hope /ID# 154053, Duarte, California, United States
🇺🇸
UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States
🇺🇸
Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States

and more 7 locations

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Phase 2

Completed

Conditions: Erosive Hand Osteoarthritis

Interventions: Biological: ABT-981
Biological: Placebo for ABT-981

First Posted Date: 2015-03-10

Last Posted Date: 2017-08-11

Lead Sponsor: AbbVie

Target Recruit Count: 132

Registration Number: NCT02384538

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy

Completed

Conditions: Parkinson's Disease (PD)

First Posted Date: 2015-03-06

Last Posted Date: 2020-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 136

Registration Number: NCT02381444

Locations: 🇩🇪
Gertrudis-Klinik /ID# 144631, Leun-biskirchen, Germany
🇩🇪
Klinikum Altenburger Land /ID# 139643, Altenburg, Germany
🇩🇪
Klinik Haag /ID# 137458, Haag, Germany

and more 24 locations

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Phase 1

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Colorectal Carcinoma
Glioblastoma Multiforme

Interventions: Drug: ABBV-221

First Posted Date: 2015-02-19

Last Posted Date: 2018-03-30

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT02365662

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸
Fundacion Jimenez Diaz, Madrid, Spain

and more 2 locations

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: ABT-494
Drug: Placebo

First Posted Date: 2015-02-19

Last Posted Date: 2023-12-27

Lead Sponsor: AbbVie

Target Recruit Count: 220

Registration Number: NCT02365649

Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-02-12

Last Posted Date: 2021-02-11

Lead Sponsor: AbbVie

Target Recruit Count: 401

Registration Number: NCT02362074

Locations: 🇨🇦
Drs. M & W Teo Inc. /ID# 148641, Penticton, British Columbia, Canada
🇨🇦
Kur, Vancouver, CA /ID# 135371, Vancouver, British Columbia, Canada
🇨🇦
Nexus Clinical Research /ID# 135411, St. John's, Newfoundland and Labrador, Canada

and more 29 locations

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: Sofosbuvir
Drug: Ribavirin

First Posted Date: 2015-02-05

Last Posted Date: 2017-12-20

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT02356562

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: adalimumab
Biological: ABT-122

First Posted Date: 2015-01-28

Last Posted Date: 2017-08-04

Lead Sponsor: AbbVie

Target Recruit Count: 240

Registration Number: NCT02349451

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Phase 2

Completed

Conditions: Glioblastoma

Interventions: Drug: Lomustine
Drug: Depatuxizumab mafodotin
Drug: Temozolomide

First Posted Date: 2015-01-22

Last Posted Date: 2020-05-22

Lead Sponsor: AbbVie

Target Recruit Count: 266

Registration Number: NCT02343406

Locations: 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷
CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France

and more 99 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy